H.C. Wainwright analyst Ed Arce raised the firm’s price target on Travere Therapeutics to $19 from $17 and keeps a Buy rating on the shares after the European Commission granted conditional marketing authorization of Filspari for the treatment of adults with primary IgA nephropathy. The firm “conservatively” projects 2024 Filspari net sales in the region to total $3.9M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
- Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
- Travere downgraded to Neutral at Guggenheim on smaller role in IgAN space
- Travere Therapeutics downgraded to Neutral from Buy at Guggenheim
